Is p53 an independent prognostic factor in patients with laryngeal carcinoma?

Cancer

Volumn 82, Issue 2, 1998, Pages 286-291

  Narayana, Ashwatha ^a,b   Vaughan, Andrew T M ^a   Gunaratne, Saroo ^a   Kathuria, Satinder ^a   Walter, Scott A ^a   Reddy, Sarada P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Radiotherapy ^*  (United States)

Author keywords

Immunohistochemistry; Laryngeal carcinoma; p53; Prognostic indicator

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GLOTTIS; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VOCAL CORD;

ACTUARIAL ANALYSIS; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLOTTIS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MICE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031964840     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<286::AID-CNCR7>3.0.CO;2-P     Document Type: Article

References (26)

1. Vogelstein B. Cancer, a deadly inheritance. Nature 1990;348:681-2.
2. Harris AL. Mutant p53 - the commonest genetic abnormality in human cancer? J Pathol 1990;162:5-6.
3. Reich NC, Oven M, Levine AJ. Two distinct mechanisms regulate the levels of cellular tumor antigen p53. Mol Cell Biol 1983;3:2143-50.
4. Finlay CA, Hinds PW, Tan TH, Eliyahn D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an HSC 70-p53 complex with an altered half life. Mol Cell Biol 1988;8:531-9.
5. Yewdell JW, Gannon JV, Lane DP, Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 1986;59:442-52.
6. Banks L, Mathlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the study of human p53 expression. Eur J Biochem 1986;159:529-34.
7. Dobaski Y, Sakamoto A, Sugimara H, Mernyei M, Mori M, Oyama T. p53 overexpression is an early event in the development of human squamous cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 1992;52:178-82.
8. Field JK, Malliri A, Butt SA, Gosney JR, Philips D, Spandidos DA, et al. p53 overexpression in end-stage squamous cell carcinoma of head and neck prior to chemotherapy treatment: expression correlates with a very poor clinical outcome. Int J Oncol 1993;3:631-5.
9. Maestro R, Dolcetti R, Gasporotto D, Doglioni C, Pelucchi S, Barzan L. High frequency of p53 gene alteration associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
10. Ogden AR, Kiddne RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992;166:389-94.
11. Vermuelen PB, Roland L, Mertens V, Van Marck E, De Bruijn EA, Van Oosterom AT, et al. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res 1996;51:164-74.
12. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. 2nd edition. Norwalk, CT: Appleton and Lange, Inc. 1994:64-81.
13. Watling DL, Gowan AM, Coltrera P. Overexpression of p53 in head and neck cancer. Head Neck 1992;16:437-44.
14. Awwad S, Jarros E, Jomes J, Lunec J. p53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;36:323-32.
15. Rudoltz MD, Benammar A, Mohiuddin M. Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 1993;26:762-72.
16. Skuse AR. The search for prognostic genetic indicators of cancer recurrence. Int J Radiat Oncol Biol Phys 1996;34:509-10.
17. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer 1991;51:6304-11.
18. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jack T, Walsh WV. A mammalian cell cycle check point pathway utilizing p53 and GADD-45 is defective. Cell 1992;71:587-97.
19. Brachman DA, Beckett M, Haraf D, Graves D, Vokes E, Yardell D. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
20. Leith JT. Letter to the editor. Cancer Res 1994;54:5021.
21. Field JR, Pavelic MD, Spandidos DA, Stambrook PJ, Jones SA, Gkuckman JL. The role of p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993;119:1118-22.
22. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J. Clin Oncol 1997;15:1030-8.
23. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
24. Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? Revisited! [editorial] J Pathol 1994;172:1-4.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
26. Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K, et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 1996;32:2242-8.